Press "Enter" to skip to content

Dr Reddy’s Q3 web revenue zooms 77% to Rs 1247 crore – Instances of India

HYDERABAD: Pharma main Dr Reddy’s Laboratories Ltd on Wednesday reported a 77% soar in consolidated revenue after tax of Rs 1,247 crore for the third quarter ended December 31, 2022, from Rs 707 crore in Q3 of FY22.
This was on a 27% enhance in revenues for the quarter at Rs 6,770 crore as towards Rs 5,320 crore in Q3 of FY22.
Whereas international generics revenues grew 33% throughout the quarter to Rs 5,924 crore from Rs 4,451 crore, that of Pharmaceutical Companies & Energetic Elements (PSAI) went up by 7% in Q3FY23 to Rs 776 crore from Rs 727 crore in Q3FY22.
North America accounted for a bit of the worldwide generics revenues, rising 64% to Rs 3,057 crore in Q3FY23 from Rs 1865 crore in Q3FY22, adopted by rising markets at Rs 1,310 crore from Rs 1,154 crore (up 14%), adopted by India revenues that grew 10% to Rs 1,127 crore from Rs 1,027 crore and Europe, which went up 6% to Rs 430 crore from Rs 406 crore.
Dr Reddy’s co-chairman & managing director GV Prasad mentioned the corporate’s sturdy monetary efficiency was supported by development within the US and Russia markets. “We proceed to strengthen our improvement pipeline to achieve extra sufferers globally,” he mentioned.

Supply hyperlink

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: